--- title: "Medicinova | 8-K: FY2025 Revenue: USD 409.66 K" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/276436519.md" datetime: "2026-02-20T11:27:21.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276436519.md) - [en](https://longbridge.com/en/news/276436519.md) - [zh-HK](https://longbridge.com/zh-HK/news/276436519.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/276436519.md) | [English](https://longbridge.com/en/news/276436519.md) # Medicinova | 8-K: FY2025 Revenue: USD 409.66 K Revenue: As of FY2025, the actual value is USD 409.66 K. EPS: As of FY2025, the actual value is USD -0.24, beating the estimate of USD -0.38. EBIT: As of FY2025, the actual value is USD -14.59 M. #### Net Sales Net sales for MediciNova, Inc. were $409,657 for the fiscal year ended December 31, 2025, with no net sales recorded in the prior fiscal year. This revenue in 2025 was recognized under an agreement with Mayo Foundation for Medical Education and Research . #### Operating Loss Operating loss for the fiscal year ended December 31, 2025, was -$13,283,002, compared to -$12,675,331 for the fiscal year ended December 31, 2024 . #### Loss Before Income Taxes Loss before income taxes was -$11,991,963 for the fiscal year ended December 31, 2025, an increase from -$11,044,012 in the prior fiscal year . #### Net Loss Attributable to Shareholders The net loss attributable to shareholders of MediciNova, Inc. was -$11,997,957 for the fiscal year ended December 31, 2025, compared to -$11,049,549 for the fiscal year ended December 31, 2024 . #### Comprehensive Loss Comprehensive loss for the fiscal year ended December 31, 2025, was -$11,989,983, increasing from -$11,066,613 in the previous fiscal year . #### Total Assets Total assets decreased to $45,603,109 as of December 31, 2025, from $55,875,926 as of December 31, 2024 . #### Total Equity (Net Assets) Total equity (net assets) decreased to $41,586,681 as of December 31, 2025, from $52,503,551 as of December 31, 2024 . #### Shareholders’ Equity Ratio The shareholders’ equity ratio was 91.2% as of December 31, 2025, a decrease from 94.0% as of December 31, 2024 . #### Cash and Cash Equivalents Cash and cash equivalents at the end of the period were $30,806,477 as of December 31, 2025, down from $40,359,738 as of December 31, 2024 . #### Cash Flows from Operating Activities Net cash used in operating activities was -$9,810,061 for the fiscal year ended December 31, 2025, an improvement from -$10,642,964 in the prior fiscal year . #### Cash Flows from Investing Activities Net cash used in investing activities was -$2,899 for the fiscal year ended December 31, 2025, compared to -$697 for the fiscal year ended December 31, 2024 . #### Cash Flows from Financing Activities Net cash provided by financing activities was $244,018 for the fiscal year ended December 31, 2025, primarily from the issuance of equity under a standby equity purchase agreement (SEPA), with no cash provided by financing activities in the prior fiscal year . #### Cost of Services Cost of services was $378,606 for the fiscal year ended December 31, 2025, with no cost of services recorded in the prior fiscal year . #### Research, Development and Patents Expenses Research, development and patents expenses were $7,154,848 for the fiscal year ended December 31, 2025, which was generally at the same level as $7,194,731 in the prior fiscal year . #### General and Administrative Expenses General and administrative expenses increased by $0.7 million to $6,159,205 for the fiscal year ended December 31, 2025, from $5,480,600 in the prior fiscal year, primarily due to SEPA fees and increased professional and investor relations expenses . #### Interest Income Interest income decreased by $0.4 million to $1,303,792 for the fiscal year ended December 31, 2025, from $1,670,804 in the prior fiscal year, mainly due to a decrease in the cash balance . #### Outlook / Guidance for Fiscal Year Ending December 31, 2026 MediciNova, Inc. plans to continue focusing its resources on the clinical development of MN-166 and MN-001, expecting research and development expenses to increase . The company anticipates operating expenses of approximately $16.2 million, an 18% increase compared to 2025 . However, MediciNova, Inc. has not provided specific consolidated forecast figures for revenues and operating income due to ongoing strategic collaborations and out-licensing activities . ### 相關股票 - [Medicinova (MNOV.US)](https://longbridge.com/zh-HK/quote/MNOV.US.md) ## 相關資訊與研究 - [BOK gov nominee Shin: Korean won liquidity is good](https://longbridge.com/zh-HK/news/281097264.md) - [Unicharm Corporation's Equity Buyback announced on February 12, 2026, has closed with 19,411,600 shares, representing 1.12% for ¥18,999.98 million.](https://longbridge.com/zh-HK/news/281657346.md) - [Bok Gov Nominee Shin: The Current Level of Korean Won Is Not That Meaningful](https://longbridge.com/zh-HK/news/281094929.md) - [Wealth First Promoters Confirm 74% Stake With No Encumbrance in FY26](https://longbridge.com/zh-HK/news/281530653.md) - [FUJIFILM Holdings Corporation announces an Equity Buyback for 13,000,000 shares, representing 1.08% for ¥30,000 million.](https://longbridge.com/zh-HK/news/281042703.md)